Abstract
Saframycin A (SFM-A), a tetrahydroisoquinoline antibiotic isolated from Streptomyces lavendulae, shows potent anti-proliferation activities against a variety of tumor cell lines, and shares the core structure with ecteinascidin 743 (ET-743), the anticancer drug for soft-tissue sarcoma. Characterization of the SFM-A biosynthetic gene cluster revealed three nonribosomal peptide synthetase genes and a series of genes encoding oxygenases. To investigate the function of sfmO2 gene, encoding a FAD-dependent monooxygenase/hydroxylase, we constructed the gene replacement mutant (sfmO2) strain S. lavendulae TL2007 and the corresponding gene complementation mutant strain S. lavendulae TL2008. A novel compound, SFM-O, was isolated from the sfmO2 replacement mutant strain and its structure was characterized by comparison to the HRMS and NMR spectra of SFM-A. These findings indicated that SfmO2 is responsible for the oxidation of ring A in the biosynthetic pathway of SFM-A, and the new compound SFM-O could be considered as an advanced intermediate in the semisynthesis of ET-743.
Similar content being viewed by others
References
Arai T, Takahashi K, Kubo A. New antibiotics, saframycins A, B, C, D and E. J Antibiot, 1977, 30: 1015–1018
Arai T, Takahashi K, Ishiguro K, Yazawa K. Increased production of saframycin A and isolation of saframycin S. J Antibiot, 1980, 33: 951–960
Lown JW, Hanstock CC, Joshua AV, Arai T, Takahashi K. Directed biosynthesis ofnew saframycin derivatives with resting cells of Streptomyces lavendulae. J Antibiot, 1983, 36: 1184–1194
Mikami Y, Takahashi K, Yazawa K, Arai T, Namikoshi M, Iwasaki S, Okuda S. Biosynthetic studies on saframycin A, a quinone antitumor antibiotic produced by Streptomyces lavendulae. J Biol Chem, 1985, 260: 344–348
Pospiech A, Cluzel B, Bietenhader J, Schupp T. A new Myxococcus xanthus gene cluster for the biosynthesis of the antibiotic saframycin Mx1 encoding a peptide synthetase. Microbiology, 1995, 141: 1793–1803
Scott JD, Williams RM. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem Rev, 2002, 102: 1669–1730
Asaoka T, Yazawa K, Mikami Y, Arai T, Takahashi K. A new saframycin, saframycin R. J Antibiot, 1982, 35: 1708–1710
Irschik H, Trowitzsch KW, Gerth K, Hofle G, Reichenbach H. Saframycin Mx1, a new natural saframycin isolated from a myxobacterium. J Antibiot, 1988, 41: 993–998
Rinehart KL, Holt TG, Fregeau NL, Stroh JG, Kieffer PA, Sun F, Li LH, Martin DG. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: Potent antitumor agents from the caribbean tunicate Ecteinascidia turbinate. J Org Chem, 1990, 55: 4512–4515
Ishiguro K, Sakiyama S, Takahashi K, Arai T. Mode of action of saframycin A, a novel heterocyclic quinone antibiotic. Inhibition of RNA synthesis in vivo and in vitro. Biochemistry, 1978, 17: 2545–2550
Lown JW, Joshua AV, Lee JS. Molecular mechanisms of binding and single-strand scission of deoxyribonucleic acid by the antitumor antibiotics saframycins A and C. Biochemistry, 1982, 21: 419–428
Plowright AT, Schaus SE, Myers AG. Transcriptional response pathways in a yeast strain sensitive to saframycin A and a more potent analog: Evidence for a common basis of activity. Chem Biol, 2002, 9: 607–618
Xing C, LaPorte JR, Barbay JK, Myers AG. Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proc Natl Acad Sci USA, 2004, 101: 5862–5866
Arai T, Takahashi K, Ishiguro K, Mikami Y. Some chemotherapeutic properties of two new antitumor antibiotics, saframycins A and C. Gann, 1980, 71: 790–796
Cuevas C, Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep, 2009, 26: 322–337
Cuevas C, Peŕez M, Martıń MJ, Chicharro JL, Carolina FR, Marıá F, Francesch A, Gallego P, Marıá Z, Calle F, Garcıá J, Polanco C, Ignacio R, Ignacio M. Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B. Org Lett, 2000, 2: 2545–2548
Hopwood DA, Genetic contributions to understanding polyketide synthases. Chem Rev, 1997, 97: 2465–2497
Epp JK, Huber ML, Turner JR, Goodson T, Schoner BE. Production of a hybrid macrolide antibiotic in Streptomyces ambofaciens and Streptomyces lividans by introduction of a cloned carbomycin biosynthetic gene from Streptomyces thermotolerans. Gene, 1989, 85: 293–301
Gokhale RS, Tsuji SY, Cane DE, Khosla C. Dissecting and exploiting intermodular communication in polyketide synthases. Science, 1999, 284: 482–485
Xue Q, Ashley G, Hutchinson CR, Santi DV. A multiplasmid approach to preparing large libraries of polyketides. Proc Natl Acad Sci USA, 1999, 96: 11740–11745
Menzella HG, Reid R, Carney JR, Chandran SS, Reisinger SJ, Patel KG, Hopwood DA, Santi DV. Combinatorial polyketide biosynthesis by de novo design and rearrangement of modular polyketide synthase genes. Nat biotechnol, 2005, 23: 1171–1176
Li L, Deng W, Song J, Ding W, Zhao QF, Peng C, Song WW, Tang GL, Liu W. Characterization of the saframycin A gene cluster from S. lavendulae NRRL 11002 revealing a nonribosomal peptide synthetase system for assembling the unusual tetrapeptidyl skeleton in an iterative manner. J Bacteriol, 2008, 23: 251–263
Koketsu K, Watanabe K, Suda H, Oguri H, Oikawa H. Reconstruction of the saframycin core scaffold defines dual Pictet-Spengler mechanisms. Nat Chem Biol, 2010, 6: 408–410
Velasco A, Acebo P, Gomez A, Schleissner C, Rodríguez P, Aparicio T, Conde S, Muñoz R, de la Calle F, Garcia JL, Sánchez-Puelles JM. Molecular characterization of the safracin biosynthetic pathway from Pseudomonas fluorescens A2-2: Designing new cytotoxic compounds. Mol Microbiol, 2005, 56: 144–154
Fu CY, Tang MC, Peng C, Li L, He YL, Liu W, Tang GL. Biosynthesis of 3-hydroxy-5-methyl-o-methyltyrosine in the saframycin/safracin biosynthetic pathway. J Microbiol Biotechnol, 2009, 19: 439–446
Mao Y, Varoglu M, Sherman DH. Molecular characterization and analysis of the biosynthetic gene cluster for the antitumor antibiotic Mitomycin C from Streptomyces lavendulae NRRL 2564. Chem Biol, 1999, 6: 251–263
Arai T, Takahashi K, Kubo A, Nakahara S. The structure of saframycin C has been established by an X-ray crystallographic analysis. This result allows the assignment of structure of the closely related saframycin B by 13C NMR spectroscopy. Tetrahedron Lett, 1979, 25: 2355–2358
Arai T, Takahashi K, Nakahara S, Kubo A. The structure of a novel antitumor antibiotic, saframycin A. Experientia, 1980, 36: 1025–1027
Lown JW, Joshua AV, Chen HH. Studies related to antitumor antibiotics. Part XXIV. High field 1H NMR analysis and conformations of saframycin A and C, Can J Chem, 1981, 59: 2945–2952
Haruyama H, Kurihara H, Kondo M. Proton nuclear magnetic relaxization; an application to the study of conformation and configuration of saframycin A. Chem Pharm Bull, 1985, 33: 905–915
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peng, C., Tang, YM., Li, L. et al. In vivo investigation of the role of SfmO2 in saframycin A biosynthesis by structural characterization of the analogue saframycin O. Sci. China Chem. 55, 90–97 (2012). https://doi.org/10.1007/s11426-011-4450-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11426-011-4450-4